BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15110630)

  • 1. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination.
    Ferraresso M; Ghio L; Tirelli S; Pedotti P; Taioli E; Edefonti A; Berardinelli L
    Transplant Proc; 2004 Apr; 36(3):685-6. PubMed ID: 15110630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?
    Ferraresso M; Ghio L; Edefonti A; Vigano S; Boschiero L; Berardinelli L
    Pediatr Transplant; 2005 Jun; 9(3):328-31. PubMed ID: 15910389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
    Konstadinidou I; Boletis JN
    Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cyclosporine on the development of immunosuppressive therapy--pediatric transplantation using cyclosporine.
    Hoyer PF; Vester U
    Transplant Proc; 2004 Mar; 36(2 Suppl):197S-202S. PubMed ID: 15041336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.
    Hu RH; Tsai MK; Lee PH
    Transplant Proc; 2004 Sep; 36(7):2105-7. PubMed ID: 15518762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.
    Praditpornsilpa K; Avihingsanon Y; Nivatvong S; Kansanabuch T; Eiam-Ong S; Tiranathanagul K; Chusil S; Tungsanga K
    Clin Transplant; 2005 Jun; 19(3):335-9. PubMed ID: 15877794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial.
    Gotti E; Perico N; Gaspari F; Cattaneo D; Lesti MD; Ruggenenti P; Segoloni G; Salvadori M; Rigotti P; Valente U; Donati D; Sandrini S; Federico S; Sparacino V; Mourad G; Bosmans JL; Dimitrov BD; Iordache BE; Remuzzi G
    Transplant Proc; 2005 Jun; 37(5):2037-40. PubMed ID: 15964332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.